Company profile: NiKang Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
Products and services
- NKT2152: Clinical-stage small molecule HIF2α inhibitor in Phase 1/2 trials for treating clear cell renal cell carcinoma and other solid tumors with targeted HIF2α blockade
- SHP2 Inhibitor: Small-molecule SHP2 inhibitor discovered and developed by NiKang, currently being evaluated in clinical trials by Erasca for SHP2 target inhibition
- NKT3447: ATP-competitive CDK2 inhibitor with reversible binding in Phase 1 trials, built to disrupt CDK2 activity for treating solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NiKang Therapeutics
Transition Bio
HQ: United States
Website
- Description: Provider of condensate technology for drug discovery and diagnostics, offering PhaseScanTM, a microfluidics-based high-throughput molecular screen to identify drug candidates and mechanisms of action; CelPhaseTM, high-content cellular imaging to visualize condensates in disease models and patient samples for target validation; and DeePhaseTM, an AI engine using proprietary datasets for target discovery and hit identification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transition Bio company profile →
InCrowd
HQ: United States
Website
- Description: Provider of a market research platform for life sciences companies to obtain real-time feedback from healthcare professionals. Offerings include MicroSurvey for short, real-time surveys; MicroTracker and Essentials for wave-over-wave tracking; InCrowd Interview for automated qualitative research; and Access/Access+ to a global panel of healthcare professionals and patients with survey support and optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InCrowd company profile →
CureClick
HQ: United States
Website
- Description: Provider of a proprietary, community-powered crowdsourcing platform that accelerates awareness and participation in clinical research and improves patient recruitment for clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CureClick company profile →
Applied BioMath
HQ: United States
Website
- Description: Provider of advanced mathematical and systems biology-driven support to help biotechnology and pharmaceutical companies accelerate and de-risk drug research and development, reducing late-stage attrition by applying these techniques at critical decision points in the drug discovery process.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied BioMath company profile →
Curio Bioscience
HQ: United States
Website
- Description: Provider of spatial transcriptomics tools for cancer biology, developmental biology, immunology, and neuroscience: Curio Seeker kits for whole transcriptome mapping of fresh-frozen tissues, compatible with eukaryotes and fitting sequencing workflows without specialized equipment; Curio Trekker for single-cell spatial mapping without deconvolution or segmentation; and the Seeker bioinformatics pipeline to process FASTQ into spatial maps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curio Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NiKang Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NiKang Therapeutics
2.2 - Growth funds investing in similar companies to NiKang Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NiKang Therapeutics
4.2 - Public trading comparable groups for NiKang Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →